These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1405037)

  • 1. Neurochemical investigation on the effects of a new diphenylpiperazine calcium antagonist, KB-2796, on the central dopaminergic system of rats.
    Ikegami A; Ozaki A; Hara H; Sukamoto T; Yamashita A; Ito K
    Jpn J Pharmacol; 1992 Apr; 58(4):399-405. PubMed ID: 1405037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chronic calcium antagonist treatment on dopamine recognition sites in rat striatum.
    Govoni S; Di Giovine S; Moresco RM; Battaini F; Trabucchi M
    Neurosci Lett; 1988 Apr; 87(1-2):173-7. PubMed ID: 3380334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of flunarizine with dopamine D2 and D1 receptors.
    Ambrosio C; Stefanini E
    Eur J Pharmacol; 1991 May; 197(2-3):221-3. PubMed ID: 1833208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flunarizine potentiates cocaine-induced dopamine release and motor stimulation in rats.
    Pani L; Kuzmin A; Stefanini E; Gessa GL; Rossetti ZL
    Eur J Pharmacol; 1990 Nov; 190(1-2):223-7. PubMed ID: 2076754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and biochemical effects of a novel calcium antagonist, KB-2796, on the central dopaminergic system.
    Ozaki A; Ikegami A; Yoshidomi M; Yamashita A; Sukamoto T
    Eur J Pharmacol; 1991 Aug; 200(2-3):311-7. PubMed ID: 1782992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competitive inhibition of [3H]spiperone binding to D-2 dopamine receptors in striatal homogenates by organic calcium channel antagonists and polyvalent cations.
    De Vries DJ; Beart PM
    Eur J Pharmacol; 1984 Oct; 106(1):133-9. PubMed ID: 6241565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of continuous administration for 12 months of amine-depleting drugs and chlorpromazine on striatal dopamine function in the rat.
    Hong M; Kilpatrick GJ; Jenner P; Marsden CD
    Neuropharmacology; 1987 Aug; 26(8):1061-9. PubMed ID: 2889161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of calcium antagonists on the dopamine system.
    Mena MA; Garcia de Yébenes MJ; Tabernero C; Casarejos MJ; Pardo B; Garcia de Yébenes J
    Clin Neuropharmacol; 1995 Oct; 18(5):410-26. PubMed ID: 8665555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats.
    Hong M; Jenner P; Marsden CD
    Neuropharmacology; 1987; 26(2-3):237-45. PubMed ID: 2884588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of [3H]dopamine uptake by flunarizine.
    Devoto P; Pani L; Kuzmin A; De Montis G
    Eur J Pharmacol; 1991 Oct; 203(1):67-9. PubMed ID: 1797556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic function in rat brain after oral administration of calcium-channel blockers or haloperidol. A microdialysis study.
    Reiriz J; Ambrosio S; Cobos A; Ballarín M; Tolosa E; Mahy N
    J Neural Transm Gen Sect; 1994; 95(3):195-207. PubMed ID: 7865175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of a novel Ca2+ channel blocker, KB-2796, on 5-HT-induced responses].
    Fujishima Y; Hara H; Shimazawa M; Yokota K; Sukamoto T
    Nihon Yakurigaku Zasshi; 1994 Jul; 104(1):19-29. PubMed ID: 8076888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of KB-2796, a new calcium antagonist, and other diphenylpiperazines on [3H]nitrendipine binding.
    Iwamoto T; Morita T; Kanazawa T; Ohtaka H; Ito K
    Jpn J Pharmacol; 1988 Oct; 48(2):241-7. PubMed ID: 2850381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprolactinaemia does not alter specific striatal 3H-spiperone binding in the rat.
    Simpson MD; Jenner P; Marsden CD
    Biochem Pharmacol; 1986 Oct; 35(19):3203-8. PubMed ID: 3768017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3- and 4-O-sulfoconjugated and methylated dopamine: highly reduced binding affinity to dopamine D2 receptors in rat striatal membranes.
    Werle E; Lenz T; Strobel G; Weicker H
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Jul; 338(1):28-34. PubMed ID: 2853303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites.
    Coupet J; Rauh CE
    Eur J Pharmacol; 1979 Apr; 55(2):215-8. PubMed ID: 456420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium antagonism by KB-2796, a new diphenylpiperazine analogue, in dog vascular smooth muscle.
    Iwamoto T; Morita T; Sukamoto T
    J Pharm Pharmacol; 1991 Aug; 43(8):535-9. PubMed ID: 1681067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral changes as a result of dotarizine or flunarizine influence on dopaminergic neurotransmission in the striatum.
    Petkov VD; Petkova B
    Acta Physiol Pharmacol Bulg; 1998; 23(1):21-5. PubMed ID: 10347616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chronic nicotine treatment and withdrawal on rat striatal D1 and D2 dopamine receptors.
    Kirch DG; Taylor TR; Creese I; Xu SX; Wyatt RJ
    J Pharm Pharmacol; 1992 Feb; 44(2):89-92. PubMed ID: 1352822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ontogeny of dopaminergic function in the rat midbrain tegmentum, corpus striatum and frontal cortex.
    Noisin EL; Thomas WE
    Brain Res; 1988 Jun; 469(1-2):241-52. PubMed ID: 3401800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.